Close
Help




JOURNAL

Clinical Medicine Insights: Therapeutics

Sitaxentan for the Oral Treatment of Pulmonary Arterial Hypertension: Benefits from Endothelin Receptor Subtype Selectivity?

Submit a Paper


Clinical Medicine Insights: Therapeutics 2009:1 111-121

Review

Published on 16 Apr 2009


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Therapeutics

Hermann A.M. Mucke

H.M. Pharma Consultancy, Wien (Vienna), Austria.

Abstract

Pulmonary arterial hypertension (PAH) is a deadly and underdiagnosed disease which causes right heart failure secondary to pressure overload resulting from the thickening of the pulmonary artery endothelium, associated with elevated levels of circulating endothelin-1. Sitaxentan was the first endothelin antagonist with high selectivity for receptor subtype A (over subtype ET-B) to gain regulatory approval for the treatment of PAH in major pharmaceutical markets. This review traces the development history of sitaxentan, summarizes the designs and results from its clinical studies, and relates the drug’s profile to that of the two other broadly available endothelin receptor antagonists, bosentan and ambrisentan. All three drugs have comparable therapeutic efficacy in the 6-minute walk test—a frequently employed standard—during the first 3–4 months of therapy. Their performance might differ slightly in other clinically relevant outcome measures, especially in longer-term treatment where fully comparable data have not yet been reported. In clinical trials of up to one year duration the propensity of sitaxentan to induce elevation of liver transaminases and hepatic failure was significantly lower than that of bosentan. As a once-daily oral drug with good tolerability sitaxentan has become a crucial element in the treatment of PAH.



Downloads

PDF  (289.94 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)




What Your Colleagues Say About Clinical Medicine Insights: Therapeutics
My recent paper in Clinical Medicine Insights: Therapeutics was the third I have published in a Libertas Academica journal.  Again, I was very pleased by the remarkable speed of publication. It took less than seven weeks from submission of the first manuscript version and two weeks from submission of the revision to the appearance of the final article.  When I had unforeseen problems with the transmission of proof corrections because of some software incompatibilities the ...
Dr Ruediger Hardeland (University of Goettingen, Germany)
More Testimonials

Quick Links


New article and journal news notification services